EPO Patent Publication: Opioid Agonist Peptides

ChangeBridge: EPO Bulletin - Peptides (C07K)

Published March 11th, 2026

Detected March 26th, 2026

Summary

The European Patent Office published patent application EP4092038A1 on March 11, 2026, related to opioid agonist peptides and their uses. The application lists Protagonist Therapeutics, Inc. as the applicant.

View original document View source feed page

What changed

The European Patent Office (EPO) has published patent application EP4092038A1, titled 'Opioid Agonist Peptides and Uses Thereof.' This publication, dated March 11, 2026, details a new invention related to opioid agonist peptides and their therapeutic applications. Protagonist Therapeutics, Inc. is listed as the applicant.

This patent publication is primarily an informational notice regarding intellectual property. It does not impose new regulatory obligations or compliance requirements on pharmaceutical companies or drug manufacturers. However, it is relevant for entities involved in the research, development, and potential commercialization of opioid-related therapeutics, as it may impact the competitive landscape and patentability of similar inventions.

Source document (simplified)

← EPO Patent Bulletin

OPIOID AGONIST PEPTIDES AND USES THEREOF

Publication EP4092038A1 Kind: A1 Mar 11, 2026

Applicants

Protagonist Therapeutics, Inc.

Inventors

ANANDAN, Sampath Kumar, ZHANG, Jie, BHANDARI, Ashok, BOURNE, Gregory Thomas, FREDERICK, Brian Troy, MATTHEAKIS, Larry C., LIU, David, MEHROTRA, Mukund M.

IPC Classifications

C07K 7/06 20060101AFI20221020BHEP A61K 38/00 20060101ALI20221020BHEP C07K 5/117 20060101ALI20221020BHEP C07K 7/02 20060101ALI20221020BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →